Zhaoyan New Drug: No undisclosed significant matters requiring disclosure were found in the company's stock trading

In an announcement from Sinogen Pharma, the closing price increase deviation value cumulatively exceeded 20% within three consecutive trading days on March 27, 2026, March 30, 2026, and March 31, 2026. After the company conducted an internal self-check and formally requested information in writing from the company’s controlling shareholder and actual controller, as of the date of this announcement, the company and the company’s controlling shareholder and actual controller confirm that there is no material information that should have been disclosed but has not been disclosed.